TPST: Tempest Therapeutics Net Sales Margin

Public company logo of Tempest Therapeutics Inc (TPST)

Due to the humanitarian status of medicine, Tempest Therapeutics (TPST) operates within a secure US perimeter, shielded from geopolitical risks. The company's revenues are based on the commercialization of TPST-1120 for the therapy of solid tumors. The emerging small-molecule ecosystem enhances the body's immune response. Final sales margins illustrate operational efficiency, while the 0.00 metric reflects current profitability dynamics.

tempesttx.com (TPST) Company Sales Margin: for the period 07/04/2022 - 11/19/2026

Tempest Therapeutics (TPST) - metric breakdowns and financial figures

- market value and analyst target forecast:
Fundamental company valuation:Tempest Therapeutics, Inc. - TPST
Finished products of Tempest Therapeutics Corp

Sales margins serve as a key indicator of the efficiency with which revenue is converted into net income. This metric determines the portion of profit remaining after deducting all operating and tax expenses. By analyzing net sales profitability, an investor identifies cycles of maximum profitability and points of critical profit compression. For Tempest Therapeutics (TPST), this indicator will reflect the future efficiency of commercializing liver cancer drugs. The trend of the curve will confirm the company's ability to monetize royalties from partners.

Who Tempest Therapeutics competes with

ONC: Net Sales Margin|Net Margin Halozyme Inc. (HALO)|Net Margin RevMed|Net Return on Sales AAPG (Ascentage Pharma Group)|Net Sales Margin CGON|UroGen Pharma - Net Return on Sales|Bicara Therapeutics - Return on Sales by Net Profit|Net Sales Margin Personalis Inc PSNL|Erasca Oncology - Net Sales Margin|Net Profit Rate DCTH (Delcath Corp)|YMAB: Net Sales Margin|AURA - Company Sales Margin|CADL (Candel Therapeutics Inc.) - Net Sales Margin|Net Return on Sales ARAY (Accuray)|Return on Sales by Net Profit SLS (SELLAS Life Sciences Group, Inc.)|ACTU - Net Margin|Net Margin Citius Oncology, Inc. CTOR|HURA - Return on Sales by Net Profit|protaratx.com - Net Sales Margin|FATE - Net Sales Margin|WHWK: Net Sales Margin|TScan Therapeutics (TCRX) - Net Sales Margin|Net Margin Champions Oncology|Net Margin XBIT|Net Sales Margin CVM|Return on Sales by Net Profit OS Therapies Inc. OSTX|Net Margin Radiopharm Theranostics Limited RADX|artivabio.com (ARTV) - Net Margin|ANL - Net Margin|Net Margin verupharma.com|XLO: Net Sales Margin|Enochian BioSciences (RENB) - Net Sales Margin|Return on Sales by Net Profit MURA|Kairos Pharma Ltd - Net Profit Margin|Net Sales Margin OKUR|CytoMed Therapeutics Limited (GDTC) - Net Profitability Margin|Net Sales Margin CRIS (Curis, Inc.)|APLM: Net Return on Sales|Tharimmune Corporation - Net Sales Margin|ADVB: Net Margin|GNPX: Net Sales Margin|CLDI (Calidi Biotherapeutics Inc.) - Net Margin|Net Margin Sunshine Biopharma, Inc.|Net Sales Margin xeneticbio.com|Net Margin Salarius (SLRX)|Return on Sales by Net Profit Purple Biotech PPBT|Net Margin American Oncology Network, Inc. AONC|BeiGene, Ltd. (BGNE) - Net Margin|Checkpoint Therapeutics Inc. - Net Sales Margin|Net Profit Rate ELEV (Elevation Oncology)|ICAD (iCAD Corp) - Return on Sales by Net Profit|Ikena Oncology, Inc. - Net Profit Rate|Return on Sales by Net Profit NTBL|VIRX: Net Profit Rate|Net Margin MorphoSys Corporation (MOR)|NAYA - Net Margin|Net Sales Margin AAPGV (Ascentage)